Inotuzumab Ozogamicin

== Information about Inotuzumab Ozogamicin ==Inotuzumab ozogamicin is a humanized monoclonal antibody-cytotoxin conjugate which is used in the therapy of refractory or relapsed acute lymphoblastic leukemia. 

Liver safety of Inotuzumab Ozogamicin

Inotuzumab ozogamicin has been linked to frequent serum enzyme elevations during therapy and with instances of clinically apparent acute liver injury, including acute sinusoidal obstruction syndrome which can be severe and even fatal. 

Mechanism of action of Inotuzumab Ozogamicin

Inotuzumab (in" oh tooz' ue mab) ozogamicin (oh" zoe ga mye' sin) is a humanized monoclonal antibody to the human CD24 cell surface marker which is highly expressed on malignant lymphoblastic leukemia cells.  The monoclonal antibody is conjugated to a cytotoxic agent from a class of calicheamicins called ozogamicin.  When inotuzumab binds to CD24, it is inteRNAlized and the ozogamicin is released by the action of lysosomal enzymes on the linker molecule that joins it to the monoclonal antibody.  The released intracellular ozogamicin causes breaks in double stranded DNA that leads to apoptotic cell death.  This monoclonal antibody conjugate has been shown to be effective in inducing remissions in refractory acute lymphoblastic leukemia and was given accelerated approval for this indication in the United States in 2017. 

Dosage and administration for Inotuzumab Ozogamicin

Inotuzumab ozogamicin is available as 0.9 mg of lyophilized powder in single dose vials under the brand name Besponsa.  The recommended dose regimen varies by body weight, day of therapy and whether treating refractory vs relapsed acute lymphoblastic leukemia. 

Side effects of Inotuzumab Ozogamicin

Common side effects include bone marrow suppression, infections, fatigue, fever, nausea, headache, abdominal pain and hemorrhage.  Less common but potentially serious side effects include severe myelosuppression, severe infections, clinically significant bleeding and hemorrhage, infusion related reactions, QTc interval prolongation and embryo-fetal toxicity.

 

The article on Inotuzumab Ozogamicin is a stub. YOU can help Wikimd by expanding it!

Medication resources

WikiMD is a sponsored by W8MD Weight loss, sleep and medical aesthetics.

Learn more

• Dailymed label info
• Scientific articles

edit 

About WikiMD

About us: WikiMD is a free medical encyclopedia and wellnesspedia moderated by medical professionals.

Our mission: Provide up to date physician reviewed health, nutrition and wellness information for free in over 100 languages.

Join us: This article is a stub. Help improve Inotuzumab Ozogamicin or others. Do not trust amateurs with your life! Join us in this effort!. Paid editors welcome.